XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 8-K - Current report - Item 1.02 Item 2.01 Item 3.01 Item 3.03 Item 5.01 Item 5.02 Item 5.03 Item 9.01

Jounce Therapeutics Inc

Announcement: JNCE 8-K Special Filing

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Announcement: JNCE 10-K/A Special Filing Amendment

Form 8-K - Current report - Item 1.01 Item 1.02 Item 2.05 Item 7.01 Item 9.01

Analyst Summary:

Jounce Therapeutics has confirmed receipt of an unsolicited proposal from Concentra Biosciences in regards to a purchase of equity in the company. The proposal valued Jounce at approximately $1.1 billion and is anticipated to be completed in Q2 of 2023, subject to regulatory and shareholder approvals. Jounce is a clinical-stage immunotherapy company focused on developing tumor-attacking therapies through biomarker-driven approaches. The board is committed to acting in the best interest of shareholders and will make further announcements in due course. Forward-looking statements were made in regards to the potential deal and subsequent shareholder approval. Investors should be aware of applicable restrictions based on their jurisdiction. Jounce cautions investors not to place undue reliance on forward-looking statements made in the document, and to inform themselves of, and observe, any applicable requirements.

Form 8-K - Current report - Item 8.01 Item 9.01

$JNCE reports unsolicited $1.1B equity proposal from Concentra Biosciences

Form 8-K - Current report - Item 7.01 Item 9.01